U.S. Markets close in 1 hr 23 mins

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
12.27-0.89 (-6.76%)
As of 2:37PM EDT. Market open.
People also watch
OSIRHALONEOSUPNTGTX
Full screen
Previous Close13.16
Open13.07
Bid12.40 x 500
Ask12.43 x 400
Day's Range12.09 - 13.63
52 Week Range7.64 - 17.47
Volume8,024,519
Avg. Volume1,673,821
Market Cap1.38B
Beta0.75
PE Ratio (TTM)64.58
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : September 11, 2017
    Capital Cube9 days ago

    MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : September 11, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MiMedx Group, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Apple Bucks Market Drop, In Buy Zone; Will These 4 Breakouts Fly?
    Investor's Business Daily28 days ago

    Apple Bucks Market Drop, In Buy Zone; Will These 4 Breakouts Fly?

    The major averages retreated modestly Wednesday afternoon. But Apple is trying to rise a second straight day and is still within the 5% buy zone following an Aug. 2 breakout in huge turnover.

  • American City Business Journalslast month

    Metro Atlanta's MiMedx to spin out subsidiary to focus on biopharma

    Marietta-based MiMedx Group, Inc. (MDXG) has signed an agreement to divest the company's subsidiary, Stability Biologics LLC, back to its original stockholders. MiMedx Group is developing and marketing regenerative and therapeutic biologics with human placental tissue allografts and patent-protected processes for multiple sectors of health care. In January of 2016, the company acquired Stability Biologics, which developed and processed bioactive bone graft products and tissue allografts.